During this period of social distancing and uncertainty, we at Open Pharma hope that all of our readers are staying safe and healthy. We also know that the deluge of information on the 2019 novel coronavirus disease (COVID-19) outbreak can be incredibly taxing on our mental health. Links to several wellbeing resources can be found … Continue reading Weekly digest: what’s happening in open science?
Blog
Weekly digest: what’s happening in open science?
Featuring new endorsements to the Open Pharma position statement on open access, a Nature Careers podcast, a meta-review of data sharing, more on coronavirus research, data visualization techniques, the STM Association’s Research Data Year, transformative agreements and the impact of preprints. Ipsen and PLOS endorse the Open Pharma position statement! via Open Pharma Open Pharma … Continue reading Weekly digest: what’s happening in open science?
New research in overall support of the Evidence [Aid]
Humanitarians working in crisis zones need real-time access to evidence. A recent study from McMaster University in Canada explored the effectiveness of Evidence Aid’s resource collections on critical decision-making
Weekly digest: what’s happening in open science?
Featuring new open access deals and fee models, developments in sharing research data, the UK MRC’s commitment to disclosing clinical trial results, and insights into the peer review process and conference guidelines. New open access deal for UK institutions via Wiley A new agreement made between Wiley and Jisc allows researchers at UK institutions to … Continue reading Weekly digest: what’s happening in open science?
Weekly digest: what’s happening in open science?
Featuring a win for transparency advocates in a federal lawsuit, the new ICMJE disclosure form, framework from cOAlition S on hybrid journals, inequalities in open access publishing, the future of scientific papers, ethical research practice, and clearing up the differences between Open Science and Open Access.
Weekly digest: what’s happening in open science?
Featuring the debunking of ‘fake news’, cardiovascular clinical trial controversy, open data in the USA, reduced lack of funding for preprint repositories, the wait for the launch of the Projekt DEAL and Wiley flagship journal, ranking and indices in science, and questions surrounding Plan S.
CBMRT US Biomedical Transparency Summit newsletter
The Center for Biomedical Research Transparency (CBMRT) hosts a free 5-year Biomedical Transparency Summit (BMTS) series in the US and Europe. The goal of BMTS is to promote discussion and collaboration on transparency across the global biomedical research ecosystem
Linking Evidence to Aid researchers in tackling the 2019 novel coronavirus outbreak
As the collection of literature and resources on the 2019 novel coronavirus outbreak increases, Evidence Aid is working to ensure links to the latest research are made discoverable
Weekly digest: what’s happening in open science?
Featuring stakeholder opinions on the proposed White House Executive Order on open access in the USA, a new data-sharing declaration and the introduction of a financial incentive for publishing negative results in Germany
Combatting the next outbreak: why open access matters
As the Open Pharma position statement reaches over 100 endorsements, we share why open access is important for public health and hear why publishing house Frontiers has endorsed the position statement.